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This article is a review of a series of three studies that proved the involvement of osteopontin as a 
prognostic marker in malignant pleural mesothelioma (MPM) cancers. The approach used involved 
synthesizing and analysing the three articles. The first proves the utilization of osteopontin and 
mesothelin for diagnostic and prognostic assessment of MPM in patients previously exposed to 
asbestos and those with pleural metastasis. The second proves that immunohistochemical analysis 
identified osteopontin to have a prognostic role from its expression in MPM. The third uses the 
specificity and sensitivity of serum osteopontin to distinguish patients with plueral mesothelioma from 
subjects with asbestos-related non-malignant diseases. Overall, these remarkable findings are important 
for understanding of expression of osteopontin in malignant mesothelial cells and in patients with MPM. 
The use of osteopontin as a prognostic marker in MPM is promising and such fine molecular studies 
certainly help in bringing osteopontin closer to clinical practice. 
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INTRODUCTION 
 
Asbestos is the major cause of malignant 
mesothelioma (MM) in the Western world 
[1,2]. In spite of the large number of indi-
viduals exposed to asbestos, only a relatively 
small percentage of them, during their 
lifetime, will develop MM, leading some 
experts to suggest that there are additional 
factors that predispose to the disease. Simian 
virus 40 (SV40), a DNA virus, has been 
implicated as a carcinogen in the formation of 
mesotheliomas. Recent studies have shown 
that SV40 sequences could be found in up to 
60 % of mesotheliomas and that 100 % of the 
infected cells express SV40 T antigen (Tag); 
however, the infected cells are not lysed by 
SV40 due to abnormally high levels of p53 
expression in mesothelial cells which binds 
Tag and limits the replication of SV40. This 
probably sets up a situation where the me-
sothelial cells infected with SV40 can acquire 
genetic mutations and a malignant phenotype 
[3-6]. 
  
Malignant pleural mesothelioma 
 
Malignant mesotheliomas are tumours that 
arise from the mesothelial cells of serosal 
surfaces such as the pleura and peritoneum. 
The single term, malignant pleural 
mesothelioma (MPM), can be misleading in 
that these tumours present with substantial 
phenotypic variability and are, therefore, 
classified according to the relative 
proportions of epithelial and spindle cells [7]. 
The median survival rate after the diagnosis 
of pleural mesothelioma is 9 to 12 months; in 
advanced cases, resection of the tumour can 
prolong survival by about 3 months [8,9]. 
Mesothelioma is an extremely aggressive 
tumour that is highly resistant to 
chemotherapy and radiotherapy. Thus, 
significant advances in the treatment of MPM 
will involve an early diagnosis to select 
candidates for therapy with curative intent 
[10]. The discovery of a marker that would 
permit an earlier diagnosis could lead to an 
increase in the proportion of patients 
diagnosed with early-stage mesothelioma in 
which a multimodal treatment, including 
surgery and radiotherapy/chemotherapy, 
would eventually result in a better outcome. 
To date, there is no recognized marker for 
the diagnosis of mesothelioma or for 
screening of at-risk asbestos-exposed 
individuals. Retrospective studies of small 
numbers of patients with pleural 
mesothelioma have attempted to identify 
biomarkers that predate symptoms in a high-
risk population. These markers include tissue 
polypeptide antigen, carcino-embryonic 
antigen, hyaluronic acid and ferritin, 
hyaluronic acid alone, cytokeratins such as 
soluble cytokeratin 19 fragment, 12-16 CA-





Osteopontin (OPN) is in the family of five 
small integrin-binding ligand N-linked 
glycoproteins (SIBLINGs1) and a 
glycophosphoproteins that was first identified 
in 1986 in osteoblasts. Osteopontin has come 
to be an emerging group of molecular tools 
that cancer cells use to facilitate their 
expansion. In normal tissues, OPN interacts 
with a variety of integrins, including αvβ1, 
αvβ3, αvβ5, α4β1, α8β1 and α9β1 as well as 
CD44 splice variant. It also exhibits reduced 
serine/theonine phosphorylation by casein 
kinase which induces the adhesion of human 
breast cancer cells almost six-fold more than 
hyperphosphorylated OPN; this highlights the 
possible modifying roles of the many post-
translational events on OPN functions. It has 
been shown to play an important role in 
tumour progression and invasion in breast, 
lung, colon, stomach, mesothelioma and 
postrate cancer [13,15]. 
 
Osteopontin has been seen as a promising 
biomarker due to its expression on gene-
expression arrays to predict survival and 
recurrence patterns in patients with pleural 
mesothelioma [16,18] and it seems especially 
interesting as a potential early diagnostic 
marker because it has been shown to 
differentiate asbestos-exposed patients from 
Alaribe et al  
Trop J Pharm Res, December 2010; 9(6): 607 
stage I mesothelioma patients. However, 
questions are always raised about the clinical 
utility of this marker especially when the 
report did not include other pleural 
malignancies and nonmalignant asbestos-
induced pleural diseases as controls 
 [19,20].  
 
This review highlights a series of three recent 
studies/articles that prove the use of 
osteopontin as a diagnostic and a marker in 
malignant pleural mesothelioma. The first 
article evaluates the diagnostic and 
prognostic value of osteopontin and soluble 
mesothelin-related peptides measured both 
in blood and pleural fluids in a series of 
patients suspected to have MPM. The 
second proves that osteopontin plays a 
prognostic role in its immunohistochemical 
expression levels, which was significantly 
reduced in long-surviving patients with 
mesothelioma and vice versa. The third 
article identifies osteopontin as a useful 
biomarker in pleural mesothelioma by 
comparing serum levels of osteopontin in a 
group of subjects with asbestos-related 
nonmalignant disease with preoperative 
levels in patients with surgically-treated 
pleural mesothelioma [10,14,17]. 
 
Osteopontin as a prognostic and diagno-
stic assessment tool for MPM  
 
Involvement of osteopontin as a prognostic 
marker in malignant pleural mesothelioma 
(MPM) has come under intense scrutiny in 
recent years. Bogdan et al [17] in their work 
to measure the diagnostic value of 
osteopontin both in blood and pleural fluid, 
recruited 112 healthy subjects previously 
exposed to asbestos (AE group) and 43 
patients with pleural metastasis of 
adenocarcinomas (Mets group), 33 patients 
with benign pleural lesions associated with 
asbestos exposure (BPLAE group), and 96 
patients with MPM. They found that there 
was low serum osteopontin in the AE group. 
Higher serum osteopontin levels were found 
in patients with BPLAE, MPM and Mets 
patients (Fig 1A). Interestingly, the authors 
discovered no statistically significant 
difference in serum osteopontin between the 
three groups of patients (Figs 1A and B) 
{MPM, Mets, and BPLAE; p > 0.38 for all 
comparisons}. Serum osteopontin has a good 
ability to distinguish between patients with 
MPM and asbestos-exposed healthy subjects 
(AE) with an area under the curve (AUC) of 
0.724  (95 %  confidence interval (CI), range: 
0.650 - 0.798), as shown in Fig 2. Serum 
osteopontin showed also a significant ability 
to distinguish patients with any pleural 
involvement (MPM, Mets or BPLAE) and 
healthy asbestos-exposed subjects (AE; AUC 
0.735; 95 % CI, range: 0.677 - 0.793) and 
patients with malignant pleural involvement 








Figure 1:  Diagnostic value of serum osteopontin and 
mesothelin in patients with MPM. (A) shows serum 
osteopontin values in MPM patients compared with 
pleural metastasis (Mets), benign pleural lesions 
associated with asbestos exposure (BPLAE), and 
healthy asbestos-exposed subjects (AE). B shows serum 
mesothelin in same patients. Horizontal lines, median 
values (A and B). 
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Figure 2:  Diagnostic value of serum osteopontin and 
mesothelin in patients with MPM. C indicates ROC curve 
for mesothelin and osteopontin when differentiating 
between MPM and healthy asbestos-exposed subjects 
(AE group). 
 
The diagnostic value was low in both AE and 
BPLAE groups and slightly higher in Mets 
patients (see Fig 1B). MPM patients depicted 
higher values of mesothelin. A statistically 
significant correlation between serum 
mesothelin and blood (serum or plasma) 
osteopontin values were found (p  < 0.02) in 
all subgroups of patients (MPM, BPLAE and 
Mets). 
 
Furthermore, osteopontin and mesothelin 
were compared as prognostic factors. It was 
discovered that median survival was lower in 
Mets group than in MPM group and that 
neither age, sex nor preural value of 
mesothelin and osteopontin were related to 
survival. However, a significant relationship 
with survival was found for serum mesothelin 
as well as serum and plasma osteopontin. 
Patients with a high mesothelin level had a 
median survival of 7 months compared with 
19 months for the low mesothelin level group. 
Similarly, patients with high serum 
osteopontin had a significantly shorter 
survival rate than patients with low serum 
osteopontin level.  
 
Osteopontin serum level was related to 
duration of asbestos exposure and showed a 
good ability to discriminate between 
asymptomatic asbestos-exposed individuals 
and early stage mesothelioma patients. The 
most interesting result of this report is the 
potential usefulness of both serum 
osteopontin and serum mesothelin as 
prognostic markers in MPM. 
 
 
Immunohistochemical analysis and the 
prognostic role of osteopontin in MPM 
 
Sussana et al, in their investigation on the 
prognostic role of osteopontin expression in 
MPM using immunohistochemical analysis, 
discovered that osteopontin reactivity was 
specifically localized in internal control cells 
(i.e., macrophages)[14]. No immunoreactivity 
was observed in normal mesothelial cells 
obtained from patients with pneumothorax or 
in the surrounding stroma. Conversely, 
hyperplastic or reactive mesothelial cells in 
the cases of nonmalignant chronic pleuritis 
showed weak immunoreactivity. Occasional 
mesenchymal and inflammatory cells in the 
extracellular matrix were positive for 
osteopontin. 
 
Osteopontin expression was observed in 
almost all MPM cases. Neoplastic cells had 
variable patterns of cytoplasmic reactivity, as 
diffuse granular or perinuclear spots, with 
intensity ranging from weak to intense. The 
percentage of distribution varied from 1 to 98 
%; therefore, the histologic scoring (HScore) 
values obtained ranged from 1 to 297 scores. 
In many samples, osteopontin reactivity 
appeared to be restricted to small, very 
strong cytoplasmic spots, immediately 
adjacent to the nucleus. This staining pattern 
probably corresponds to osteopontin protein 
in the Golgi apparatus and/or secretory 
vesicles. 
 
In the LS (long-term survival) group, the 
distribution of HScore values of osteopontin 
expression varied from 5 to 250 (median, 50), 
whereas in the SS (short term survival) 
group, HScore values varied from 30 to 297 
(median, 180). The difference was 
statistically significant (p < 0.0001; Mann-
Whitney U), as shown in Figure 3A. No 
statistically significant difference (p = 0.3817; 
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Mann-Whitney U) was found between the 
pooled LS and SS groups, in which the 
distribution of HScore values ranged from 5 
to 297 (median, 145), and the CC group 
(consecutive MPM group), ranging from 1 to 
285 (median, 132). The two groups were 
therefore statistically comparable (see Figure 
3B). Furthermore, survival analysis of 
patients revealed that the univariate analyses 
comparing the LS and SS groups, 
osteopontin expression and performance 
status were significant prognostic factors (P < 
0.00001 and p = 0.02, respectively), whereas 
no other variables correlated with survival. In 
multivariate analysis, however, only 
osteopontin retained significance as an 
independent predictor of survival. 
  
From the above findings, osteopontin 
expression was statistically correlated to 
MPM in a subgroup of long-surviving 
patients, as opposed to short surviving 
patients. These data indicate that increased 
osteopontin expression levels may be a 
predictive marker of survival at the time of 
MPM diagnosis. 
 
Figure 3: Distribution of osteopontin (OPN) 
immunohistochemical hsitologic scoring (HScore) values 
in malignant pleural mesothelioma (MPM).  A, OPN 
HScore values were lower in long-term survival (LS) than 
in short-term survival (SS) cases (p<.0001; Mann-
Whitney µ) B, OPN Hscore values in the pooled LS and 
SS (LS + SS) cases were comparable to the consecutive  
MPM group (CC) (p = .3817; Mann-Whitney µ).  Boxes 




 percentailes); Whiskers, 
the major and minor values, and lines I the boxes, 
median values. 
 
Use of specificity and sensitivity of serum 
osteopontin as a distinguishing tool  
 
Harvey et al [9] undertook a study on serum 
osteopontin levels in patients with MPM due 
to exposure to asbestos, subjects with cancer 
but no exposure to asbestos as well as 
subjects without cancer and no exposure to 
asbestos. They discovered that the mean 
(±SE) serum level of osteopontin in the entire 
group of subjects who were exposed to 
asbestos was 30 ± 3 ng/mL (range, 2 to 221 
ng/mL; 95 %CI, which did not differ 
significantly from that in subjects without 
exposure to asbestos (20 ± 4 ng/mL, p = 
0.06). The levels in age-matched controls 
with no exposure to asbestos and normal 
radiographs did not differ significantly 
according to age from those in the group 
exposed to asbestos. Fig 4B shows that in 
the group with exposure to asbestos, there 
were no significant differences in osteopontin 
levels according to sex (p = 0.19) or the 
presence or absence of pleural plaques 
(P=0.88), as Fig 4C illustrates. The subgroup 
with lung fibrosis had a significantly higher 
mean level of osteopontin than the subgroup 
without fibrosis (43 vs. 23 ng/mL; 95 %CI, 7 
to 33 ng/mL, respectively, with p = 0.004) (Fig 
4D), and the mean levels were significantly 
higher with 10 or more years of exposure 
than with fewer than 10 years of exposure 
(34 ng/mL vs. 16 ng/mL; 95 %CI for the 
difference, 4 to 33; p = 0.02) (Fig 4C). The 
highest levels of serum osteopontin were 
found in subjects who had both plaques and 
fibrosis (56 ± 13 ng/mL). Serum osteopontin 
levels were significantly lower in age-
matched unexposed controls than in subjects 
with asbestos exposure and plaques and 
fibrosis (mean age in both groups, 64 ± 3 
years): 14 ± 6 vs. 56 ± 13 ng/mL (p = 0.03). 
 
Among the subjects with exposure to 
asbestos, osteopontin levels were 
significantly lower in subjects with a normal 
chest radiograph (21 ± 5 ng/mL), subjects 
with plaques (23 ± 3 ng/mL), and subjects 
with fibrosis (32 ± 7 ng/mL) than in those who 
had plaques and fibrosis (56 ± 13 ng/mL, p = 
0.004). A multiple regression analysis that 
included age, duration of exposure to 
asbestos, presence or absence of fibrosis, 
presence or absence of plaques, and 
International Labor Organization radiography 
score, was performed. Only the duration of  
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Figure 4: Mean (±SE) serum osteopontin levels 
according to exposure status and age, sex, years of 
exposure to asbestos, and radiographic findings. There 
were no significant differences in osteopontin levels 
between subjects exposed to asbestos and age-matched 
controls with no exposure to asbestos for subjects 
according to age and year of exposure (Panel 3A). No 
significant differences in osteopontin levels were noted 
with respect to sex (Panel 3B). Osteopontin levels rose 
as the duration of exposure to asbestos increased (Panel 
3C) and the degree of radiographic abnormality 
increased (Panel 3D). The p value for Panel D is for the 




exposure to asbestos and the radiographic 
findings were independently associated with 
osteopontin levels (p = 0.001 and p < 0.001, 
respectively), with zero-order correlation 
coefficients of 0.357 and 0.399, respectively. 
Additionally, the mean serum osteopontin 
level in the group with pleural mesothelioma 
differed significantly from that in the group 
exposed to asbestos. There were no 
significant differences in mean serum 
osteopontin levels among patients with stage 
I mesothelioma, stage II mesothelioma or 
stage III mesothelioma. However, the means 
in all these stages differed significantly from 
the mean in the group exposed to asbestos 
(30 ± 3 ng/mL; range, 2 to 221 ng/mL; 95 
%CI, with p < 0.001). Moreover, serum 
osteopontin levels in the subjects with 
exposure to asbestos and plaques and 
fibrosis differed significantly from those in the 
patients with pleural mesothelioma. Mean 
osteopontin levels were similar in men and 
women with mesothelioma and did not vary 
according to the histologic characteristics of 
the tumour or the history of asbestos 
exposure. 
 
In their immunohistochemical findings [9], the 
authors showed that out of the 38 of the 76 
patients with mesothelioma for whom 
osteopontin staining was carried out on 
tumour tissue, 36 (out of the 38 samples) 
were positive for osteopontin. They showed 
cytoplasmic staining in at least 50 % of 
tumour cells, and staining intensity ranged 
from 1 in the case of 13 samples to 3 in the 
case of 15 samples; 8 samples had a staining 
intensity of 2. Osteopontin was seen in all 
pleural mesothelioma variants: 19 of 20 
epithelial tumour 15 of 16 mixed tumours, 
and 2 of 2 sarcomatoid tumours. Lung 
parenchyma and adjacent normal pleura 
were negative for osteopontin. Fibroblasts in 
tumour-associated stroma were infrequently 
weakly positive, and the media and intima of 
vessels showed weak positivity. 
 
The above study shows the apparent ability 
of an enzyme-linked immunosorbent assay 
(ELISA) for osteopontin to identify early 
pleural mesothelioma (fig 5E, 5F -stage I). 
This finding, if confirmed, would have 
immediate clinical applications because the 
use of therapy could potentially influence 
survival among patients with stage I pleural 
mesothelioma. Immunohistochemical 
analysis showed that osteopontin was 
present in the tumour cells of pleural 
mesothelioma but not in the stroma. The 
sensitivity and specificity of serum 
osteopontin for distinguishing patients with 
pleural mesothelioma from subjects with 
asbestors related non malignant diseases 
revealed an approach of 0.9 specificity of  
 
 
Alaribe et al  










     
Figure 5: Sensitivity and specificity of serum osteopontin 
for distinguishing patients with pleural mesothelioma 
from subjects with asbestos-related nonmalignant 
disease. In Panel 4A, an analysis that included all 76 
patients with pleural mesothelioma and 69 subjects with 
exposure to asbestos revealed an area under the curve 
(AUC) of 0.888 (95 %CI, range 0.826 to 0.934). In Panel 
4B, the use of a cutoff value of 10.9 ng of osteopontin 
per mL showed a high sensitivity for the early detection 
of mesothelioma. In Panel 4C, the use of a cutoff value 
of 48.3 ng of osteopontin per mL to minimize the total 
classification error had a sensitivity of 77.6 %. In Panel 
4D, an analysis that included the 13 patients with stage I 
mesothelioma and the 69 subjects with exposure to 
asbestos revealed an AUC of 0.906. In Panel E, the use 
of a cutoff value of 9.5 ng of osteopontin per mL showed 
a high sensitivity for the early detection of stage I 
mesothelioma. In Panel 4F, the use of a cutoff value of 
62.4 ng of osteopontin per mL to minimize the total 




area under curve (AUC). These findings 
provide support for the specificity of 
osteopontin as a marker for transformed 
mesothelial cells. 
 
Furthermore, the above data suggest that 
serum osteopontin levels could be used to 
discriminate between persons with exposure 
to asbestos who do not have early pleural 
mesothelioma and those with exposure to 
asbestos who do have early pleural 
mesothelioma, regardless of the histologic 
type of the mesothelioma. Osteopontin levels, 
however, are also elevated in other types of 
cancers, including gastrointestinal, laryngeal, 
and urinary neoplasms, and these cancers 
have been weakly associated with exposure 
to asbestos. 
                                                                        
Consequences and advantages of 
osteopontin as a marker in MPM                                                     
 
The median survival after diagnosis of pleural 
mesothelioma is 9 to 12 months [8-9]. In 
advanced cases, resection of the tumour can 
prolong survival by about 3 months. Patients 
with stage IA disease, however, can survive 
for five or more years if the tumour is 
promptly resected. Unfortunately, the 
difficulty in detecting early disease means 
that less than 5 percent of patients with 
pleural mesothelioma present with stage IA 
disease. Therefore, a marker or series of 
biomarkers that can predict the development 
of mesothelioma or detect pleural 
mesothelioma in its early stages in 
populations with exposure to asbestos would 
be of considerable value. 
 
Osteopontin has been pin-pointed as an early 
marker for MPM diagnosis by a series of 
recent studies, although Bodgan et al [17] 
pointed out that the use of osteopontin as an 
MPM screening marker is expected to be 
difficult because the incidence of the disease 
is very low, even in asbestos-exposed 
population. Consequently, most patients with 
a positive test will, infact, be false positive but 
at least, osteopontin could be used as a first 
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specific assay in the subgroup of osteopontin 
positive patients. Furthermore, the complexity 
of osteopontin as a molecule and its several 
distinct forms should also be considered. 
Bogdan et al [17] found mesothelin to be a 
better MPM diagnostic marker than 
osteopontin in non-epitheloid MPM but 
despite good specificity, the poor sensitivity 
of mesothelin makes it insufficient for use as 
a unique screening marker. Notwithstanding, 
the results depend on the choice of the assay 
used. Therefore, future quantification of other 
soluble isoforms of osteopontin could 
possibly give better results. Interestingly, 
Bogdan et al [17] discovered osteopontin to 
be a useful potential prognostic marker in 
MPM. Similarly, Sussana et al [14] 
discovered osteopontin to be a significant 
prognostic factor from its expression and 
performance status on survival and 
multivariate analysis of patients. This 
prognostic role of osteopontin demonstrated 
in MPM patients is independent of other 
prognostic factors such as sex, age, stage 
and histologic type, though its serum 
measurement level was of low diagnostic 
usefulness owing to the lack of specificity; 
nevertheless, its expression was statistically 
correlated with a subgroup of long-surviving 
patients with MPM, as opposed to patients 
with short-term survival. These data indicate 
that increased osteopontin expression levels 
may be a predictive marker of survival at the 
time of MPM diagnosis. Consequently, more 
aggressive initial treatment targeting the 
osteopontin protein with antibodies and 
immunotherapeutic strategies may be 
envisaged. 
 
Furthermore, the most important finding by 
Harvey et al was the apparent ability of an 
enzyme-linked immunosorbent assay 
(ELISA) for osteopontin to identify early 
pleural mesothelioma (stage 1). This makes 
osteopontin a potential factor for immediate 
clinical application in the identification of 
patients with stage 1 pleural mesothelioma. 
Combination of radiographic findings and 
serum levels of osteopontin could be used to 
stratify the risk of pleural mesothelioma in 
populations with exposure to asbestos. 
Immunohistochemical analysis supported 
osteopontin as a marker for transformed 
mesothelioma cells because of its expression 
on the tumor cells of pleural mesothelioma 
but not in the stroma. 
 
Harvey et al’s [9] data suggest that serum 
osteopontin levels could be used to 
discriminate between persons with exposure 
to asbestos who do not have early pleural 
mesothelioma and those with exposure to 
asbestos who have early pleural 
mesothelioma, regardless of the histologic 
type of the mesothelioma. Moreover, the fact 
that area under the curve (AUC) approached 
0.9 suggests that osteopontin level has a 
positive predictive power equivalent to that of 
CA-125 for ovarian cancer (Fig 4A). In 
addition, osteopontin level has been elevated 
in other cancers, such as laryngeal, urinary 
neoplasm, gastrointestinal cancers, which 
have been weakly associated with exposure 




One can suggest that asbestos workers with 
high osteopontin levels who do not appear to 
have mesothelioma should be evaluated to 
rule out the presence of other cancers. 
Mesothelioma histologic subtype and blood 
levels of mesothelin and osteopontin were 
independent prognostic factors for survival 
because they probably reflect different 
aspects of tumour biology. This is also 
sustained by the absence of tight correlations 
between values of osteopontin and 
mesothelin. Further studies are needed to 
explain how mesothelin and osteopontin are 
produced, secreted, and involved in 
mesothelioma tumour progression. Kinetic 
studies will also be important to evaluate the 
value of these markers in monitoring patient 
response to therapy. 
 
Since mesothelioma is known to be an 
extremely destructive tumour and is highly 
resistant to chemotherapy and radiotherapy, 
significant advances in treatment of MPM will 
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mean early diagnosis to select candidates for 
therapy with curative intent. More research 
work should be undertaken to improve on the 
specificity of osteopontin as a marker that 
would permit an earlier diagnosis could lead 
to an increase in the proportion of patients 
diagnosed with early-stage mesothelioma in 
which a multimodal treatment, including 
surgery and radiotherapy/chemotherapy, 
would eventually result in a better outcome.  
 
Furthermore, this review strongly suggests 
that detection of osteopontin levels among a 
cohort of individuals exposed to asbestos 
could represent a useful prognostic marker to 
identify those at higher risk for MM with the 
result that this subgroup of high risk 
individuals could be closely monitored for 
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